← All stocks

Pelthos Therapeutics Inc.

PTHS Net buying
CIK 0001919246 #4321 in the set updated 18 Sep 2026
Bought (12 mo)
$999.98K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$441.33K
$120.79K on a plan · $0.00 straight out of an exercise
Sold at will
$320.55K
5 of 21 sales
Net
+$558.65K
+$679.44K against sales at will

By person

8 insiders · 23 transactions

There is no salary here to measure against. Pelthos Therapeutics Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Davis Todd C
Director
$999.98K (2)
+$999.98K
1,575,834
$42.98M
+3,851%
Friedberg Ezra M
Director
$314.23K (10)
−$314.23K
111,042
$3.03M
+160.8%
Francis Knuettel II
CFO, Treas & Secty
$40.26K (1)
−$40.26K
30,841
$841.14K
−15.0%
Greenleaf Peter
Director
$37.50K (4) scheduled
−$37.50K
23,884
$651.40K
−6.3%
Pauls Matthew
Director
$37.00K (4) scheduled
−$37.00K
14,364
$391.75K
−3.4%
Malamut Richard
Director
$12.34K (2) scheduled
−$12.34K
27,422
$747.89K
−2.1%
LIGAND PHARMACEUTICALS INC entity
Director
1,500,000
$40.91M
Einhorn Andrew J.
Director
12,000
$327.28K

No percentages here. This company's share count has moved by a factor of 2.0 over the window, from 3,042,143 to 6,103,813 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Francis Knuettel II
22 May 2026
CFO, Treas & Secty
Sell indirect
1,500
$26.84
$40.26K
Friedberg Ezra M
25 Nov 2025
Director
Sell indirect
2,000
$28.01
$56.01K
Friedberg Ezra M
25 Nov 2025
Director
Sell indirect
1
$28.50
$28.50
Friedberg Ezra M
25 Nov 2025
Director
Sell indirect
2,000
$28.14
$56.27K
Friedberg Ezra M
25 Nov 2025
Director
Sell indirect
5,999
$28.00
$167.97K

What was left out

Form 4 filings counted 16
Amendments (4/A) skipped 9
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 0
Sales at will 5
Transactions with no price 0
Shares from compensation/vesting 37,756
History held since 23 Feb 2024